National Pharmacy Health & Leadership Alliance Verify a MemberMember Login
NPHLANational Pharmacy Health & Leadership Alliance
Apply for Membership

01MetabolicWhat Changed TodayUpdated

What changed today in Metabolic: 5 trial updates

Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.

By NPHLA IntelligencePublished Last updated Automated from official records

The signal

NPHLA tracked 5 new official records on this desk today: 5 trial updates.

Why this matters

GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.

What changed

  1. New trial registered: RESIST-MIND (Functional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight Loss)[1]
  2. New trial registered: IMPACT (The Impact of Incretins on Fat-free Mass, Muscle Strength and Functional Capacity)[2]
  3. New trial registered: CLEAR-GLP1 (24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the…)[3]
  4. New trial registered: A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity[4]
  5. Trial status changed to “Enrolling by invitation”: BioM (Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine)[5]
  6. Also reported by Pharmacy Times: “Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care”.[6]

Who this affects

  • Weight-management clinics
  • Med spas
  • Pharmacists
  • Prescribers
  • Medical directors
  • Practice owners & operators

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

NPHLA takeaway

These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.

Source file

  1. [1]
  2. [2]
  3. [3]
  4. [4]
  5. [5]
  6. [6]
    Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care

    News reportingPharmacy TimesIndustry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.

Update timeline

  1. First published.
  2. Added 1 new official record.